İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

Akademisyen

DİLEK AKYÜZLÜ

PROFESÖR

ANKARA ÜNİVERSİTESİ ADLİ BİLİMLER ENSTİTÜSÜ ADLİ BİYOLOJİ ANABİLİM DALI

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Toksikoloji

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 127
  • Proje 0
  • Kitap 0
  • Bildiri 115
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 13 Q2 12 Q3 12 Q4 3
WoS (JCR) Q1 11 Q2 9 Q3 9 Q4 7
TR Index 15 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 0
Üst %10 makale 2
Ort. yüzdelik 35.0%
Üst %1 payı 0.0%
Üst %10 payı 1.8%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 127 yayın

Scopus (SJR)
Q1 13 Q2 12 Q3 12 Q4 3
WoS (JCR)
Q1 11 Q2 9 Q3 9 Q4 7
TR Index
15 makale

Makale listesi

  1. 2025 Pharmacoepigenetics in schizophrenia: Predicting drug response World Journal of Psychiatry DOI 10.5498/wjp.v15.i7.107597 YÖKSİS JCR Q2 OpenAlex 70.0%
  2. 2025 Effects of PDYN 68-bpVNTR, BDNF rs6265, OPRD1 rs569356 and OPRM1 rs2075572 polymorphisms on opioid-methamphetamine co-use Environmental Toxicology and Pharmacology DOI 10.1016/j.etap.2025.104714 YÖKSİS SJR Q1 JCR Q1 OpenAlex 57.3%
  3. 2025 Genotype and Allele Frequencies of AKR1C3 rs3763676 and rs12529 Variations in a Turkish Population: Novel PCR-RFLP Assays Russian Journal of Genetics DOI 10.1134/S1022795425700826 YÖKSİS SJR Q4 JCR Q4 OpenAlex 25.8%
  4. 2025 Association of SOD1 rs36232792 with opioid use disorder and a novel PCR-RFLP method for SOD2 rs5746136 Pharmacogenomics DOI 10.1080/14622416.2025.2490467 YÖKSİS SJR Q3 JCR Q4 OpenAlex 6.5%
  5. 2025 Evaluation of hsa-miR-29a-3p expression and diazepam biotransformation via CYP2C19 in alcohol withdrawal syndrome Environmental Toxicology and Pharmacology DOI 10.1016/j.etap.2025.104861 YÖKSİS SJR Q1 JCR Q1 OpenAlex 35.8%
  6. 2025 Development of a sample preparation and analysis method for therapeutic monitoring of diazepam and major metabolite in alcohol withdrawal syndrome treatment Journal of Pharmaceutical and Biomedical Analysis DOI 10.1016/j.jpba.2025.116805 YÖKSİS SJR Q2 JCR Q2 OpenAlex 78.8%
  7. 2025 P06-05 Exploring the role of CYP2C19*2 (rs4244285)gene polymorphism in diazepam pharmacokinetics among Turkish Alcohol Withdrawal Syndrome patients Toxicology Letters DOI 10.1016/j.toxlet.2025.07.243 YÖKSİS SJR Q2 JCR Q2 OpenAlex 27.8%
  8. 2024 OPRM1 rs2075572 has potential to affect plasma buprenorphine level in opioid users, but not OPRM1 rs562859 Neuroscience Letters DOI 10.1016/j.neulet.2024.137846 YÖKSİS SJR Q2 JCR Q4 OpenAlex 72.6%
  9. 2024 Effect of MAOA rs1465108 polymorphism on susceptibility to substance/alcohol use disorder: a novel PCR-RFLP assay for the detection of MAOA rs1465108. MOLECULAR BIOLOGY REPORTS DOI 10.1007/s11033-024-09366-z YÖKSİS SJR Q2 JCR Q3 OpenAlex 58.9%
  10. 2024 A case control study investigating the methylation levels of GHRL and GHSR genes in alcohol use disorder Molecular Biology Reports DOI 10.1007/s11033-024-09585-4 YÖKSİS SJR Q2 JCR Q3 OpenAlex 54.1%
  11. 2024 Personalized medicine and opioid use disorder World J Psychiatry DOI 10.5498/wjp.v14.i9.1285 YÖKSİS JCR Q2 OpenAlex 80.4%
  12. 2023 OPRD1 rs569356 polymorphism has an effect on plasma norbuprenorphine levels and dose/kg-normalized norbuprenorphine values in individuals with opioid use disorder Environ Toxicol Pharmacol DOI 10.1016/j.etap.2023.104143 YÖKSİS SJR Q1 JCR Q1 OpenAlex 77.7%
  13. 2023 Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and with the symptoms of depression, anxiety, craving and withdrawal. Pharmacogenomics DOI 10.2217/pgs-2023-0037 YÖKSİS SJR Q3 JCR Q3 OpenAlex 59.9%
  14. 2023 Effect of PDYN and OPRK1 polymorphisms on the risk of alcohol use disorder and the intensity of depressive symptoms Alcohol and Alcoholism DOI 10.1093/alcalc/agad036 YÖKSİS SJR Q2 JCR Q3 OpenAlex 78.1%
  15. 2022 Effects of UGT2B7 rs7662029 and rs7439366 polymorphisms on sublingual buprenorphine metabolism in heroin addicts: An improved PCR-RFLP assay for the detection of rs7662029 polymorphism Environmental Toxicology and Pharmacology DOI 10.1016/j.etap.2022.103902 YÖKSİS SJR Q1 JCR Q1 OpenAlex 85.2%
  16. 2022 Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use European Journal of Pharmacology DOI 10.1016/j.ejphar.2022.174862 YÖKSİS SJR Q1 JCR Q1 OpenAlex 36.7%
  17. 2022 Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder Environmental Toxicology and Pharmacology DOI 10.1016/j.etap.2022.103979 YÖKSİS SJR Q1 JCR Q1 OpenAlex 75.8%
  18. 2022 The involvement of miRNAs in CYP450 gene expression: A brief review of the literature ASOS Yayinevi DOI 10.29228/jrp.122 YÖKSİS TR Index SJR Q3 JCR Q4 OpenAlex 39.7%
  19. 2022 GHSR rs2232165 Gen Polimorfizminin Genotiplendirilmesi için PCR-RFLP Yönteminin Optimizasyonu ve Türk Erkeklerinde Alel Frekansının Belirlenmesi. Afyon Kocatepe Üniversitesi Fen ve Mühendislik Bilimleri Dergisi DOI 10.35414/akufemubid.1137753 YÖKSİS TR Index OpenAlex 15.4%
  20. 2022 Association of Pro-Ghrelin Leu72Met Polymorphism with Acylated Ghrelin Level and Alcohol Use Disorder: A Preliminary Study Bağımlılık Dergisi DOI 10.51982/bagimli.996238 YÖKSİS TR Index OpenAlex 36.7%

Akademisyenlere dön